查詢結果分析
相關文獻
- 口服標靶藥物引起之肺毒性
- 蘇力菌素對大鼠口服及肺毒性之評估
- 大鼠氣管內重覆暴露於氯化鎘之亞急毒性研究
- High-Dose Steroid Pulse Therapy for the Treatment of Severe Alopecia Areata
- Gallium Scintigraphy in Lung Toxicity Induced by Sauropus Androgynus
- Amiodarone肺毒性
- Amiodarone Pulmonary Toxicity--A Case Report
- Erlotinib引起之間質性肺炎:案例報告與文獻回顧
- 疑似amiodarone引起肺毒性之案例:個案報告及文獻回顧
- Amiodarone引起的肺毒性
頁籤選單縮合
題 名 | 口服標靶藥物引起之肺毒性=Pulmonary Toxicity Associated with Oral Targeted Agents |
---|---|
作 者 | 童玟津; 郭正睿; 簡素玉; | 書刊名 | 藥學雜誌 |
卷 期 | 26:3=104 2010.09[民99.09] |
頁 次 | 頁69-73 |
分類號 | 418.31 |
關鍵詞 | 口服標靶藥物; 肺毒性; 高劑量類固醇; Oral targeted agents; Pulmonary toxicity; High dose glucocorticoids; |
語 文 | 中文(Chinese) |
中文摘要 | 口服標靶治療藥物提供癌症病人許多治療選擇,提高許多方便性與治療成果,其嚴重副作用雖然少見或罕見,但發生時多數造成嚴重結果甚至致命,例如肺毒性,因此應小心謹慎監測這類嚴重副作用。 分子標靶藥品治療引起之肺毒性屬嚴重副作用中較常見之不良反應,但目前無清楚之臨床治療準則,及明確方法確認肺毒性實為藥品所引起,必須先排除是否為伺機性感染、放射線治療引起的肺部傷害或有癌症之肺部轉移,因為症狀不明顯,因此當使用分子標靶藥品後於短時間內即出現肺炎,且肺炎經類固醇治療後獲得改善,肺毒性極可能為分子標靶藥品造成。 當病人出現肺毒性後,是否繼續使用分子標靶藥品,或中斷治療,或是改用其他替代藥品,應視個別病人臨床狀況做出最適當的決定,當肺部毒性較嚴重時應停用藥品,但目前無確立有效的治療,使用類固醇亦可能增加發生伺機性感染,因此當發生肺毒性時建議使用高劑量類固醇且進行短期治療,避免長期治療增加伺機性感染發生。 |
英文摘要 | Oral targeted agents could be another choice to cancer patients, and the oral portion of the regimen greatly increased patient convenience. But the adverse drug reactions may be severe and potentially life-threatening, such as pulmonary toxicity, even the incidence is rare or infrequent. We should carefully monitor the serious adverse drug reactions. Pulmonary toxicity associated with targeted agents is relatively frequent and the diagnosis should be done once careful investigations have excluded alternative explanations, including opportunistic infections, radiation-induced lung injury, and metastatic involvement of the lungs. There are no clearly defined criteria for drug-induced lung diseases. Because signs and symptoms are generally non-specific, the diagnosis usually remains one of exclusion. A presumptive diagnosis can be made when pneumonitis develops shortly after the initiation of treatment, an alternative explanation for the respiratory compromise is lacking, and the pneumonitis resolves soon after withdrawal of the presumed agent and/or after glucocorticoid treatment. For patients who develop lung toxicity during treatment with a targeted agent, the decision to continue treatment, interrupt therapy, or switch to an alternative agent must be carefully considered based upon the clinical circumstances, and the nature and severity of the pulmonary toxicity. No specific treatment has proven effective besides discontinuation of the suspected offending agent. The use of glucocorticoids is often recommended in the more severe cases, but based upon anecdotal reports. Although the risk of opportunistic infection may be slightly increased, a short course of high dose glucocorticoids is often considered appropriate in these situations. |
本系統中英文摘要資訊取自各篇刊載內容。